Published in Endocr Relat Cancer on May 03, 2012
Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer. Endocr Relat Cancer (2014) 1.45
Androgen receptor (AR) positive vs negative roles in prostate cancer cell deaths including apoptosis, anoikis, entosis, necrosis and autophagic cell death. Cancer Treat Rev (2013) 1.05
Decoding the androgen receptor splice variants. Transl Androl Urol (2013) 1.01
Synergistic antitumour activity of sorafenib in combination with tetrandrine is mediated by reactive oxygen species (ROS)/Akt signaling. Br J Cancer (2013) 0.95
Suppression of natural killer cells by sorafenib contributes to prometastatic effects in hepatocellular carcinoma. PLoS One (2013) 0.93
Induction of cancerous stem cells during embryonic stem cell differentiation. J Biol Chem (2012) 0.88
Effects of sorafenib on C-terminally truncated androgen receptor variants in human prostate cancer cells. Int J Mol Sci (2012) 0.88
Adaptive responses of androgen receptor signaling in castration-resistant prostate cancer. Oncotarget (2015) 0.87
Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status. BMC Cancer (2015) 0.85
Combinatorial high-throughput experimental and bioinformatic approach identifies molecular pathways linked with the sensitivity to anticancer target drugs. Oncotarget (2015) 0.82
Spheroid culture of LuCaP 147 as an authentic preclinical model of prostate cancer subtype with SPOP mutation and hypermutator phenotype. Cancer Lett (2014) 0.82
Evaluation of in vivo responses of sorafenib therapy in a preclinical mouse model of PTEN-deficient of prostate cancer. J Transl Med (2015) 0.80
Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma. Clin Cancer Res (2015) 0.80
Targeting Androgen Receptor (AR)→IL12A Signal Enhances Efficacy of Sorafenib plus NK Cells Immunotherapy to Better Suppress HCC Progression. Mol Cancer Ther (2016) 0.79
The prostate cancer blocking potential of the histone deacetylase inhibitor LBH589 is not enhanced by the multi receptor tyrosine kinase inhibitor TKI258. Invest New Drugs (2012) 0.77
NSK-01105, a novel sorafenib derivative, inhibits human prostate tumor growth via suppression of VEGFR2/EGFR-mediated angiogenesis. PLoS One (2014) 0.75
Effects of RAF inhibitors on PI3K/AKT signalling depend on mutational status of the RAS/RAF signalling axis. Oncotarget (2016) 0.75
Bax/Bak-independent mitochondrial depolarization and reactive oxygen species induction by sorafenib overcome resistance to apoptosis in renal cell carcinoma. J Biol Chem (2017) 0.75
Interleukin-27 augments the inhibitory effects of sorafenib on bladder cancer cells. Braz J Med Biol Res (2017) 0.75
Increasing AR by HIF-2α inhibitor (PT-2385) overcomes the side-effects of sorafenib by suppressing hepatocellular carcinoma invasion via alteration of pSTAT3, pAKT and pERK signals. Cell Death Dis (2017) 0.75
Cancer statistics, 2010. CA Cancer J Clin (2010) 103.28
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med (2004) 32.09
Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med (2011) 27.58
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res (2004) 21.36
Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science (2009) 13.87
The development of androgen-independent prostate cancer. Nat Rev Cancer (2001) 11.88
Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1. Mol Cell (2006) 7.18
In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet (1995) 6.60
MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2. Proc Natl Acad Sci U S A (1993) 5.13
A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med (1999) 4.20
HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell (2004) 3.79
Degradation of Mcl-1 by beta-TrCP mediates glycogen synthase kinase 3-induced tumor suppression and chemosensitization. Mol Cell Biol (2007) 3.23
Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation. J Biol Chem (2005) 3.08
Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst (2001) 3.06
Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line. Cancer Res (2002) 2.99
Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am J Pathol (1996) 2.97
The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene (2005) 2.89
Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res (2006) 2.65
Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system. Br J Cancer (1999) 2.34
MCL1 provides a window on the role of the BCL2 family in cell proliferation, differentiation and tumorigenesis. Leukemia (2002) 2.17
Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer. Cancer Res (2004) 2.15
PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer. J Pathol (2009) 2.13
Frequent inactivation of PTEN in prostate cancer cell lines and xenografts. Cancer Res (1998) 2.10
A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer. Ann Oncol (2007) 2.03
A phase II clinical trial of sorafenib in androgen-independent prostate cancer. Clin Cancer Res (2008) 1.87
Elevated AKT activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis. J Biol Chem (2001) 1.65
The PIM1 kinase is a critical component of a survival pathway activated by docetaxel and promotes survival of docetaxel-treated prostate cancer cells. J Biol Chem (2008) 1.46
The antiapoptotic effect of IL-6 autocrine loop in a cellular model of advanced prostate cancer is mediated by Mcl-1. Oncogene (2006) 1.42
Novel role of Stat1 in the development of docetaxel resistance in prostate tumor cells. Oncogene (2006) 1.40
Inhibition of the acetyltransferases p300 and CBP reveals a targetable function for p300 in the survival and invasion pathways of prostate cancer cell lines. Mol Cancer Ther (2011) 1.39
Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer. BJU Int (2009) 1.37
A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV. Br J Cancer (2007) 1.33
Sorafenib inhibits STAT3 activation to enhance TRAIL-mediated apoptosis in human pancreatic cancer cells. Mol Cancer Ther (2010) 1.31
FDA approves sorafenib for patients with inoperable liver cancer. Gastroenterology (2008) 1.20
Class III beta-tubulin expression predicts prostate tumor aggressiveness and patient response to docetaxel-based chemotherapy. Cancer Res (2010) 1.18
Androgen receptor levels are upregulated by Akt in prostate cancer. Endocr Relat Cancer (2011) 1.16
CCL2 is induced by chemotherapy and protects prostate cancer cells from docetaxel-induced cytotoxicity. Prostate (2010) 1.14
Prostate cancer cells (LNCaP) generated after long-term interleukin 6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype. Clin Cancer Res (2001) 1.13
Vitamin K enhancement of sorafenib-mediated HCC cell growth inhibition in vitro and in vivo. Int J Cancer (2010) 1.10
Overcoming chemotherapy resistance in prostate cancer. Clin Cancer Res (2011) 1.06
Mechanisms of endocrine therapy-responsive and -unresponsive prostate tumours. Endocr Relat Cancer (2005) 1.02
Sorafenib induces apoptosis and autophagy in prostate cancer cells in vitro. Int J Oncol (2010) 1.01
Sorafenib enhances the antitumor effects of chemoradiation treatment by downregulating ERCC-1 and XRCC-1 DNA repair proteins. Mol Cancer Ther (2011) 0.96
A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive castration resistant prostate cancer. Invest New Drugs (2011) 0.95
Results from a monocentric phase II trial of erlotinib in patients with metastatic prostate cancer. Ann Oncol (2008) 0.93
Sorafenib sensitizes (-)-gossypol-induced growth suppression in androgen-independent prostate cancer cells via Mcl-1 inhibition and Bak activation. Mol Cancer Ther (2011) 0.93
The androgen receptor pathway is by-passed in prostate cancer cells generated after prolonged treatment with bicalutamide. Prostate (2006) 0.90
The multikinase inhibitor sorafenib induces caspase-dependent apoptosis in PC-3 prostate cancer cells. Asian J Androl (2010) 0.89
SOCS-3 antagonises the proliferative and migratory effects of fibroblast growth factor-2 in prostate cancer by inhibition of p44/p42 MAPK signalling. Endocr Relat Cancer (2010) 0.87
Multikinase inhibitor sorafenib exerts cytocidal efficacy against Non-Hodgkin lymphomas associated with inhibition of MAPK14 and AKT phosphorylation. Br J Haematol (2011) 0.84
Enhanced antiproliferative and proapoptotic effects on prostate cancer cells by simultaneously inhibiting androgen receptor and cAMP-dependent protein kinase A. Int J Cancer (2010) 0.84
Phase II trial of sunitinib for the therapy of progressive metastatic castration-refractory prostate cancer after previous docetaxel chemotherapy. Clin Genitourin Cancer (2008) 0.83
In vitro and in vivo antitumor efficacy of docetaxel and sorafenib combination in human pancreatic cancer cells. Curr Cancer Drug Targets (2010) 0.80
The mutational landscape of prostate cancer. Eur Urol (2013) 2.14
Interleukin-6 regulation of prostate cancer cell growth. J Cell Biochem (2005) 1.73
Epithelial-to-mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR-205. Am J Pathol (2012) 1.48
Interleukin-6 activates PI3K/Akt pathway and regulates cyclin A1 to promote prostate cancer cell survival. Int J Cancer (2008) 1.48
Soluble gp130 regulates prostate cancer invasion and progression in an interleukin-6 dependent and independent manner. J Urol (2011) 1.41
Inhibition of the acetyltransferases p300 and CBP reveals a targetable function for p300 in the survival and invasion pathways of prostate cancer cell lines. Mol Cancer Ther (2011) 1.39
Late penile metastasis from primary bladder carcinoma. Urology (2003) 1.32
Expression and function of androgen receptor coactivators in prostate cancer. J Steroid Biochem Mol Biol (2004) 1.31
Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor. Endocr Relat Cancer (2008) 1.30
Transcription factor Stat5 synergizes with androgen receptor in prostate cancer cells. Cancer Res (2008) 1.21
Stem-like cells with luminal progenitor phenotype survive castration in human prostate cancer. Stem Cells (2012) 1.19
Interleukin-6 trans-signalling differentially regulates proliferation, migration, adhesion and maspin expression in human prostate cancer cells. Endocr Relat Cancer (2010) 1.18
Oxidative stress-related aging: A role for prostate cancer? Biochim Biophys Acta (2008) 1.16
Frozen section analysis-guided organ-sparing approach in testicular tumors: technique, feasibility, and long-term results. Urology (2003) 1.14
The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study. Prostate (2011) 1.13
Androgen deprivation increases p300 expression in prostate cancer cells. Cancer Res (2007) 1.12
p300 regulates androgen receptor-independent expression of prostate-specific antigen in prostate cancer cells treated chronically with interleukin-6. Cancer Res (2005) 1.10
Down-regulation of suppressor of cytokine signaling-3 causes prostate cancer cell death through activation of the extrinsic and intrinsic apoptosis pathways. Cancer Res (2009) 1.09
Accelerated in vivo growth of prostate tumors that up-regulate interleukin-6 is associated with reduced retinoblastoma protein expression and activation of the mitogen-activated protein kinase pathway. Am J Pathol (2003) 1.07
Androgen receptors in prostate cancer. J Urol (2003) 1.07
Long-term androgen-ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells. Prostate (2004) 1.06
Occurrence of polyorchidism in a young man. Urology (2002) 1.05
PIAS1 is increased in human prostate cancer and enhances proliferation through inhibition of p21. Am J Pathol (2012) 1.02
Adipose tissue-derived mesenchymal stem cells expressing prodrug-converting enzyme inhibit human prostate tumor growth. Mol Ther (2009) 0.98
Interleukin-6 regulates androgen receptor activity and prostate cancer cell growth. Mol Cell Endocrinol (2002) 0.98
Long-term results of laparoscopic retroperitoneal lymph node dissection: a single-center 10-year experience. Urology (2004) 0.97
The androgen receptor co-activator CBP is up-regulated following androgen withdrawal and is highly expressed in advanced prostate cancer. J Pathol (2004) 0.96
The transcriptional co-activator cAMP response element-binding protein-binding protein is expressed in prostate cancer and enhances androgen- and anti-androgen-induced androgen receptor function. Am J Pathol (2003) 0.95
Suppressor of cytokine signaling (SOCS)-1 is expressed in human prostate cancer and exerts growth-inhibitory function through down-regulation of cyclins and cyclin-dependent kinases. Am J Pathol (2009) 0.94
Metastatic spermatocytic seminoma--an extremely rare disease. Eur Urol (2005) 0.93
Current mouse and cell models in prostate cancer research. Endocr Relat Cancer (2013) 0.92
Mcl-1 is regulated by IL-6 and mediates the survival activity of the cytokine in a model of late stage prostate carcinoma. Adv Exp Med Biol (2008) 0.91
Transcriptional coactivators p300 and CBP stimulate estrogen receptor-beta signaling and regulate cellular events in prostate cancer. Prostate (2010) 0.90
The androgen receptor pathway is by-passed in prostate cancer cells generated after prolonged treatment with bicalutamide. Prostate (2006) 0.90
Suppressor of cytokine signaling-3 antagonizes cAMP effects on proliferation and apoptosis and is expressed in human prostate cancer. Am J Pathol (2006) 0.90
Androgen receptor co-activators in the regulation of cellular events in prostate cancer. World J Urol (2011) 0.90
Oligomeric proanthocyanidin complexes (OPC) exert anti-proliferative and pro-apoptotic effects on prostate cancer cells. Prostate (2008) 0.89
SOCS2 correlates with malignancy and exerts growth-promoting effects in prostate cancer. Endocr Relat Cancer (2014) 0.89
High-risk human papillomavirus E7 oncoprotein detection in cervical squamous cell carcinoma. Clin Cancer Res (2007) 0.89
Regulation of growth of prostate cancer cells selected in the presence of interleukin-6 by the anti-interleukin-6 antibody CNTO 328. Prostate (2006) 0.89
Suppressor of cytokine signalling-3 is up-regulated by androgen in prostate cancer cell lines and inhibits androgen-mediated proliferation and secretion. Endocr Relat Cancer (2007) 0.89
A role for neurotensin in bicalutamide resistant prostate cancer cells. Prostate (2007) 0.89
Androgen receptor signaling in prostate cancer. Cancer Metastasis Rev (2014) 0.89
SOCS-3 antagonises the proliferative and migratory effects of fibroblast growth factor-2 in prostate cancer by inhibition of p44/p42 MAPK signalling. Endocr Relat Cancer (2010) 0.87
Identification of genes involved in estrogenic action in the human prostate using microarray analysis. Genomics (2004) 0.86
Molecular aspects of androgenic signaling and possible targets for therapeutic intervention in prostate cancer. Steroids (2013) 0.85
Prostate cancer cells generated during intermittent androgen ablation acquire a growth advantage and exhibit changes in epidermal growth factor receptor expression. Prostate (2004) 0.85
Long-term experience with carboplatin monotherapy for clinical stage I seminoma: a retrospective single-center study. Urology (2002) 0.85
Prosaposin upregulates AR and PSA expression and activity in prostate cancer cells (LNCaP). Prostate (2007) 0.85
Differential involvement of reactive oxygen species and nucleoside transporters in cytotoxicity induced by two adenosine analogues in human prostate cancer cells. Prostate (2009) 0.83
Acquisition of agonistic properties of nonsteroidal antiandrogens after treatment with oncostatin M in prostate cancer cells. Clin Cancer Res (2002) 0.83
Akacid-medical-formulation, a novel biocidal oligoguanidine with antitumor activity reduces S-phase in prostate cancer cell lines through the Erk 1/2 mitogen-activated protein kinase pathway. Int J Oncol (2006) 0.82
Posttraumatic high-flow priapism in children: noninvasive treatment by color Doppler ultrasound-guided perineal compression. Urology (2007) 0.82
Role of the protein tyrosine phosphatase SHP-1 in Interleukin-6 regulation of prostate cancer cells. Prostate (2010) 0.82
Laparoscopic retroperitoneal lymph node dissection: description of the nerve-sparing technique. Urology (2002) 0.81
Interleukin-6 polymorphism: expression and pleiotropic regulation in human prostate cancer. J Urol (2005) 0.81
Metastatic spermatocytic seminoma--an extremely rare disease: Part 2. Eur Urol (2006) 0.80
New insights into the role of interleukin-6 in human prostate cancer. J Urol (2009) 0.80
SOCS-3 antagonizes pro-apoptotic effects of TRAIL and resveratrol in prostate cancer cells. Prostate (2011) 0.79
IL6 sensitizes prostate cancer to the antiproliferative effect of IFNα2 through IRF9. Endocr Relat Cancer (2013) 0.79
[Chemotherapy for prostate cancer]. Wien Klin Wochenschr (2008) 0.79
Crinum latifolium leave extracts suppress immune activation cascades in peripheral blood mononuclear cells and proliferation of prostate tumor cells. Sci Pharm (2011) 0.79
Nuclear exclusion of the androgen receptor by melatonin. J Steroid Biochem Mol Biol (2002) 0.78
Studies on androgen receptor mutations and amplification in human prostate cancer. Methods Mol Med (2003) 0.78
Increased resistance to trail-induced apoptosis in prostate cancer cells selected in the presence of bicalutamide. Prostate (2007) 0.78
Erratum: STAT3 regulated ARF expression suppresses prostate cancer metastasis. Nat Commun (2015) 0.78
Identification of the FHL2 transcriptional coactivator as a new functional target of the E7 oncoprotein of human papillomavirus type 16. J Virol (2006) 0.77
Retrospective multicentre study of carboplatin monotherapy for clinical stage I seminoma. BJU Int (2010) 0.77
Involvement of interleukin-1β mediated nuclear factor κB signalling pathways to down-regulate prostate-specific antigen and cell proliferation in LNCaP prostate cancer cells. Cell Biol Int (2012) 0.76
Single institution experience with the transobturator sling suspension system AdVance® in the treatment of male urinary incontinence: mid-term results. Int Braz J Urol (2011) 0.76
Identification of mu-crystallin as an androgen-regulated gene in human prostate cancer. Prostate (2009) 0.75
Mechanism of 2-chloroadenosine toxicity to PC3 cell line. Prostate (2006) 0.75
Editorial comment on: human prostate fibroblasts induce growth and confer castration resistance and metastatic potential in LNCaP cells. Eur Urol (2009) 0.75
Genetic markers in prostate cancer: progress and limitations. Eur Urol (2012) 0.75